S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
NYSE:BVS

Bioventus (BVS) Stock Price, News & Analysis

$5.16
+0.02 (+0.39%)
(As of 03/27/2024 ET)
Today's Range
$5.10
$5.28
50-Day Range
$4.33
$5.75
52-Week Range
$0.80
$6.08
Volume
327,705 shs
Average Volume
175,327 shs
Market Capitalization
$408.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.67

Bioventus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
48.6% Upside
$7.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of Bioventus in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$46,928 Sold Last Quarter
Proj. Earnings Growth
150.00%
From $0.16 to $0.40 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.90 out of 5 stars

Medical Sector

206th out of 939 stocks

Surgical & Medical Instruments Industry

23rd out of 98 stocks

BVS stock logo

About Bioventus Stock (NYSE:BVS)

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

BVS Stock Price History

BVS Stock News Headlines

The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
What Wall Street expects from Repro Medical System's earnings
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
A Preview Of Bioventus's Earnings
Bioventus Inc. Cl A
Bioventus: Bullish On Path To Profitability
Bioventus Inc Class A
See More Headlines
Receive BVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/28/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Fax
N/A
Employees
970
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.67
High Stock Price Target
$9.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+48.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-156,230,000.00
Pretax Margin
-23.64%

Debt

Sales & Book Value

Annual Sales
$512.34 million
Cash Flow
$0.80 per share
Book Value
$2.80 per share

Miscellaneous

Free Float
56,129,000
Market Cap
$408.52 million
Optionable
Not Optionable
Beta
0.48
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Mark L. Singleton (Age 54)
    Senior VP & CFO
    Comp: $444.12k
  • Mr. Robert Claypoole (Age 52)
    President, CEO & Director
  • Mr. Mike Crowe B.S.
    M.B.A., Senior Vice President of Operations
  • Mr. David Crawford
    Vice President of Investor Relations & Treasurer
  • Mr. Anthony D'Adamio (Age 63)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $618.29k
  • Ms. Katrina J. Church J.D. (Age 62)
    Senior VP & Chief Compliance Officer
  • Ms. Helen Leupold
    Senior VP & Chief Human Resources Officer
  • Mr. Larry Chen
    Managing Director of China & Asia Pacific

BVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Bioventus stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BVS shares.
View BVS analyst ratings
or view top-rated stocks.

What is Bioventus' stock price target for 2024?

3 brokers have issued 12-month price targets for Bioventus' shares. Their BVS share price targets range from $7.00 to $9.00. On average, they predict the company's stock price to reach $7.67 in the next year. This suggests a possible upside of 48.6% from the stock's current price.
View analysts price targets for BVS
or view top-rated stocks among Wall Street analysts.

How have BVS shares performed in 2024?

Bioventus' stock was trading at $5.27 on January 1st, 2024. Since then, BVS shares have decreased by 2.1% and is now trading at $5.16.
View the best growth stocks for 2024 here
.

When is Bioventus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our BVS earnings forecast
.

How were Bioventus' earnings last quarter?

Bioventus Inc. (NYSE:BVS) issued its quarterly earnings data on Monday, November, 8th. The company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.11. The business had revenue of $108.89 million for the quarter, compared to the consensus estimate of $105.48 million. Bioventus had a positive trailing twelve-month return on equity of 2.25% and a negative net margin of 30.49%.

What guidance has Bioventus issued on next quarter's earnings?

Bioventus issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of 0.120-0.200 for the period, compared to the consensus earnings per share estimate of 0.330. The company issued revenue guidance of $520.0 million-$535.0 million, compared to the consensus revenue estimate of $517.8 million.

When did Bioventus IPO?

Bioventus (BVS) raised $126 million in an initial public offering on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity served as the underwriters for the IPO.

Who are Bioventus' major shareholders?

Bioventus' stock is owned by a number of institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (7.59%), Vanguard Group Inc. (1.55%), Vanguard Group Inc. (1.55%), Kent Lake Capital LLC (0.68%), Charles Schwab Investment Management Inc. (0.23%) and Stephens Inc. AR (0.18%). Insiders that own company stock include Anthony D'adamio, Anthony P Bihl III, John A Bartholdson, John Nosenzo, Juniper Investment Company, Ll, Katrina J Church, Kenneth Michael Reali, Mark Leonard Singleton and William A Hawkins.
View institutional ownership trends
.

How do I buy shares of Bioventus?

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BVS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners